Glaxo's credit rating suffers

Thursday 09 March 1995 00:02 GMT

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Glaxo's credit rating suffers

Glaxo, the phamaceutical giant which has won control of Wellcome, has lost its AAA credit rating from Moody's Investors Service. Its long-term debt is rated A1. Moody's said the rating reflected the substantial debt burden Glaxo will take on to complete its £9bn purchase of Wellcome.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Stay up to date with notifications from The Independent

Thank you for registering

Glaxo's credit rating suffers

Join our commenting forum

Thank you for registering